department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Epkinly · pharmadog

pharmadog
drugs
Epkinly

drug

patient view →

epcoritamab

Marketedupdated 2mo ago

by Genmab AS

Approved

community read0 votes

indications

investigational

DLBCL

all catalysts(5)

approval · 5

EPKINLY (EPCORITAMAB-BYSP) — FDA approval

EPKINLY (EPCORITAMAB-BYSP) — FDA approval

EPKINLY (EPCORITAMAB-BYSP) — FDA approval

EPKINLY (EPCORITAMAB-BYSP) — FDA approval

EPKINLY (EPCORITAMAB-BYSP) — FDA approval

News(0)

no news has mentioned this drug yet

brand

Epkinly

generic

epcoritamab-bsyp

indication

Diffuse Large B-Cell Lymphoma

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

tagApproval20 co-mentions · 5 sources
drugEPKINLY20 co-mentions · 5 sources
companyGenmab US Inc10 co-mentions · 5 sources

Trials studying epcoritamab

phase2Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)active not recruitingn=543
phase3A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in Chinaactive not recruitingn=72
phase2Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)active not recruitingn=78
phase2Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphomarecruitingn=18
phase2Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndromeactive not recruitingn=195
phase3Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphomarecruitingn=1,095
phase2A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphomarecruitingn=496
phase2First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphomaactive not recruitingn=666

more trials →